US 12,171,810 B2
Angiogenesis promoter and therapeutic method
Tetsushi Taguchi, Tsukuba (JP)
Assigned to National Institute for Materials Science, Tsukuba (JP)
Appl. No. 17/281,718
Filed by NATIONAL INSTITUTE FOR MATERIALS SCIENCE, Tsukuba (JP)
PCT Filed Oct. 2, 2019, PCT No. PCT/JP2019/038933
§ 371(c)(1), (2) Date Mar. 31, 2021,
PCT Pub. No. WO2020/071429, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 2018-189217 (JP), filed on Oct. 4, 2018.
Prior Publication US 2021/0386833 A1, Dec. 16, 2021
Int. Cl. A61K 38/39 (2006.01); A61K 35/60 (2006.01); A61P 9/00 (2006.01)
CPC A61K 38/39 (2013.01) [A61K 35/60 (2013.01); A61P 9/00 (2018.01)] 7 Claims
 
1. A method for promoting angiogenesis in a mammal subject with a peripheral artery disease, comprising administering to the mammal subject a pharmaceutically effective amount of an angiogenesis promoter comprising at least one compound selected from the group consisting of a gelatin derivative of formula (1) and a crosslinked product of the gelatin derivative,

OG Complex Work Unit Chemistry
wherein Gltn is a gelatin residue;
L is a single bond or a divalent linking group;
R1 and R2 are each independently a hydrogen atom, or a hydrocarbon group having from 1 to 20 carbon atoms, provided that at least one of R1 and R2 is a hydrocarbon group;
wherein the angiogenesis promoter is free of a growth factor; and
wherein the peripheral artery disease is treated.